WO2005040196A3 - Pif peptides biologic activities, site of action, and the antibody to detect pif - Google Patents

Pif peptides biologic activities, site of action, and the antibody to detect pif Download PDF

Info

Publication number
WO2005040196A3
WO2005040196A3 PCT/US2004/035382 US2004035382W WO2005040196A3 WO 2005040196 A3 WO2005040196 A3 WO 2005040196A3 US 2004035382 W US2004035382 W US 2004035382W WO 2005040196 A3 WO2005040196 A3 WO 2005040196A3
Authority
WO
WIPO (PCT)
Prior art keywords
pif
peptides
well
pregnancy
treatment
Prior art date
Application number
PCT/US2004/035382
Other languages
French (fr)
Other versions
WO2005040196A2 (en
Inventor
Eytan R Barnea
Original Assignee
Bioincept Llc
Eytan R Barnea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioincept Llc, Eytan R Barnea filed Critical Bioincept Llc
Priority to CA2584690A priority Critical patent/CA2584690C/en
Priority to EP04796370A priority patent/EP1680442B1/en
Priority to AU2004284097A priority patent/AU2004284097B2/en
Priority to NZ547139A priority patent/NZ547139A/en
Priority to AT04796370T priority patent/ATE516493T1/en
Publication of WO2005040196A2 publication Critical patent/WO2005040196A2/en
Priority to IL175063A priority patent/IL175063A/en
Publication of WO2005040196A3 publication Critical patent/WO2005040196A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Abstract

A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection. Further, polyclonal antibodies against PIF peptides were generated that serve for precise measurements of PIF in biological fluids. They document pregnancy presence and viability as well it helps for monitoring pregnancies at risk in humans as well as in farm and non farm animals, improving animal husbandry, where currently no specific pregnancy test exists. Also the PIF antibodies may have additional therapeutic properties for treatment of HIV, and malaria.
PCT/US2004/035382 2003-10-22 2004-10-22 Pif peptides biologic activities, site of action, and the antibody to detect pif WO2005040196A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2584690A CA2584690C (en) 2003-10-22 2004-10-22 Pif peptides biologic activities, site of action, and the antibody to detect pif
EP04796370A EP1680442B1 (en) 2003-10-22 2004-10-22 Pif peptides biologic activities
AU2004284097A AU2004284097B2 (en) 2003-10-22 2004-10-22 PIF peptides biologic activities, site of action, and the antibody to detect PIF
NZ547139A NZ547139A (en) 2003-10-22 2004-10-22 Use of preimplantation factor peptides to treat intolerence to embryo implantation
AT04796370T ATE516493T1 (en) 2003-10-22 2004-10-22 BIOLOGICAL EFFECTS OF PIF PEPTIDES
IL175063A IL175063A (en) 2003-10-22 2006-04-20 Use of pif peptides in the manufacture of a medicament for treating intolerance to embryo implantation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51337003P 2003-10-22 2003-10-22
US60/513,370 2003-10-22
US48224403A 2003-12-22 2003-12-22
US10/482,244 2003-12-22

Publications (2)

Publication Number Publication Date
WO2005040196A2 WO2005040196A2 (en) 2005-05-06
WO2005040196A3 true WO2005040196A3 (en) 2006-08-17

Family

ID=34526220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035382 WO2005040196A2 (en) 2003-10-22 2004-10-22 Pif peptides biologic activities, site of action, and the antibody to detect pif

Country Status (5)

Country Link
AU (1) AU2004284097B2 (en)
CA (1) CA2584690C (en)
IL (1) IL175063A (en)
NZ (1) NZ547139A (en)
WO (1) WO2005040196A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755787B (en) 2001-07-02 2016-05-18 倍奥英赛普特有限责任公司 For novel detection method and the PIF peptide of PIF
US8222211B2 (en) 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7723289B2 (en) 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
WO2012119072A2 (en) 2011-03-02 2012-09-07 Bioincept, Llc Compositions and methods for treatment of intracellular damage
WO2014165282A1 (en) 2013-03-12 2014-10-09 Institute of Arthritis Research, LLC Immunologically active polypeptide
EP3060924B1 (en) * 2013-10-22 2022-06-01 Bioincept LLC Pif-transfected cells and methods of use
AU2015317771A1 (en) * 2014-09-16 2017-04-06 Bioincept, Llc Compositions and methods for treating acute radiation syndrome
EP3341739A4 (en) * 2015-08-28 2019-07-10 BioIncept LLC Mutant peptides and methods of treating subjects using the same
AU2016317574A1 (en) 2015-08-28 2018-03-29 Bioincept, Llc Compositions and methods for the treatment of neurodamage
WO2021258048A2 (en) * 2020-06-18 2021-12-23 University Of Miami Reagents, pharmaceutical formulations, and methods for treating and preventing viral infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755787B (en) 2001-07-02 2016-05-18 倍奥英赛普特有限责任公司 For novel detection method and the PIF peptide of PIF
WO2004053086A2 (en) * 2002-12-06 2004-06-24 Epimmune, Inc. Plasmodium falciparum antigens and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GONZALEZ ET AL.: "PREIMPLANTATION FACTORS (PIF) EMBRYO-DERIVED IMMUNOMODULATORY PEPTIDES: POSSIBLE IMPLICATIONS FOR MATERNAL RECOGNITION AND ALLOGRAFT TOLERANCE", AME.J. OF REPROD IMMUN., vol. 47, no. 6, 2002, XP003000084 *
ROUSSEV ET AL.: "A novel bioassay for detection of preimplantation factor (PIF)", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 33, 1995, pages 68 - 73, XP002966955 *
ROUSSEV ET AL.: "Development and Validation of an assay for measuring preimplantation factor (PIF) of embryonal arigin", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 35, 1996, pages 281 - 287, XP008067941 *

Also Published As

Publication number Publication date
CA2584690A1 (en) 2005-05-06
IL175063A0 (en) 2006-08-20
AU2004284097B2 (en) 2011-05-12
WO2005040196A2 (en) 2005-05-06
NZ547139A (en) 2009-12-24
IL175063A (en) 2011-10-31
CA2584690C (en) 2015-10-06
AU2004284097A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
Pantoja et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus
IL194987A0 (en) Compositions and methods for modulating the immune system
Li et al. Monocyte surface expression of Fcγ receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus
WO2005040196A3 (en) Pif peptides biologic activities, site of action, and the antibody to detect pif
Cornwell et al. Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques
EP1855719A4 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
Skallová et al. Decreased level of novelty seeking in blood donors infected with Toxoplasma
MA31225B1 (en) Tie cytomegalovirus for human antibody cells and use.
Robbertse et al. Bovine immune factors underlying tick resistance: integration and future directions
WO2006024466A3 (en) Test device for the in vitro diagnosis of multi-analyte tests and the use thereof
Gogacz et al. Fas-related apoptosis of peritoneal fluid macrophages in endometriosis patients: understanding the disease
Krzyzowska et al. Role of Fas/FasL in regulation of inflammation in vaginal tissue during HSV-2 infection
Jun et al. Protective effect of CXCR3+ CD4+ CD25+ Foxp3+ regulatory T cells in renal ischemia-reperfusion injury
Carlos et al. Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE‐mediated reaction
Massi et al. Immune function alterations in mice tolerant to Δ9-tetrahydrocannabinol: functional and biochemical parameters
Kane et al. Prospects and pitfalls of pregnancy-associated malaria vaccination based on the natural immune response to Plasmodium falciparum VAR2CSA-expressing parasites
Okusaga et al. 19 Toxoplasma gondii, the Immune System, and Suicidal Behavior
RU2273029C2 (en) Method and set for determination of allergen-induced activation of basophils in assay of hypersensitivity to some substances
Mijbel et al. Seroprevalence of Toxoplasma gondii and Its Effect on the Levels of Dopamine and Adrenaline in Humans.
Al-Musawi et al. Relationship between TH1, TH2 immune responses and serum SOD activity in scabies
Plotnick et al. Home management of cats and dogs with diabetes mellitus: common questions asked by veterinarians and clients
Cubero et al. IL-15 re-programming compensates for NK cell mitochondrial dysfunction in HIV-1 infection
Wang et al. Neutralization of IL-4 reverses the nonresponsiveness of CD4+ T cells to regulatory T-cell induction in non-responder mouse strains
Bonakdar et al. Natural killer cells exhibit an activated phenotype in peripheral blood mononuclear cells of renal allograft rejection recipients: a preliminary study.
WO2009010614A8 (en) Use of a new isolate of neospora caninum for the development of diagnostic tests and for preparation of products for treatment and prevention of the infection caused by neospora

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 175063

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004284097

Country of ref document: AU

Ref document number: 547139

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004796370

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 584/MUMNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004284097

Country of ref document: AU

Date of ref document: 20041022

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004284097

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004796370

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2584690

Country of ref document: CA